Conditions

This post was originally published on this site I-Mab Biopharma is planning the first-in-human U.S. clinical study evaluating the safety, tolerability, and efficacy of its investigational candidate TJC4 as a treatment for solid tumors and lymphoma. The Phase 1/1b trial will explore TJC4 alone and in combination with other therapies, and is expected to launch…

This post was originally published on this site Exposure to glyphosate, a common broad-spectrum herbicide used worldwide, increases the risk of non-Hodgkin’s lymphoma (NHL) by 41 percent in humans, a study says. The study, “Exposure to Glyphosate-Based Herbicides and Risk for Non-Hodgkin Lymphoma: A Meta-Analysis and Supporting Evidence,” were published in Mutation Research/Reviews in Mutation…

This post was originally published on this site The National Cancer Institute (NCI) has awarded a five-year $12.5 million grant to City of Hope that may help improve treatment by using a vaccine, develop an immunotherapy to shut down a gene involved in B-Cell non-Hodgkin’s lymphoma, and understand who is at risk of developing a…

This post was originally published on this site A research team at Yale School of Medicine successfully treated a person with disfiguring sarcoidosis with Xeljanz (tofacitinib) — an existing approved treatment against rheumatoid arthritis — resulting in a near-complete disappearance of skin lesions. The findings were published in the New England Journal of Medicine in…

This post was originally published on this site Two cardiologists in the Netherlands are using an artificial intelligence (AI) tool called the VMS Heart Analysis System, developed by Ventripoint Diagnostics, for the early diagnosis of pulmonary hypertension in sarcoidosis patients. With this tool, Marco Post, MD, PhD, and Marloes Huitema, MD, at the St. Antonius…

This post was originally published on this site Deaths attributed to sarcoidosis as the primary underlying cause increased between 1999 and 2016 in the United States, according to a recent observational study. The study, “Sarcoidosis deaths in the United States: 1999–2016,” published in the journal Respiratory Medicine, compared death rates among different regions, races, genders,…

This post was originally published on this site The U.S. Food and Drug Administration (FDA) is updating its 2015 draft guidelines for drug discovery in rare diseases, with new guidance on natural history — how disorders such as spinal muscle atrophy (SMA) run their course if untreated — the choice of “efficacy endpoints” in clinical…

This post was originally published on this site A case study diagnosing sarcoidosis upon autopsy in a patient with acute respiratory distress syndrome (ARDS) of unknown cause highlights the importance of physicians taking into account this uncommon disease association for quicker diagnosis and treatment. The study, “Sarcoidosis Presenting as Acute Respiratory Distress Syndrome,” was published in…

This post was originally published on this site More than half of all deaths related to asbestos exposure is caused by malignant mesothelioma, a new study has shown. The study, “Risk Factors of Mortality from All Asbestos-Related Diseases: A Competing Risk Analysis,” was published in the journal Canadian Respiratory Journal. Asbestos is known to be responsible for several…

This post was originally published on this site The development and commercialization of TNB-383B — an anti-BCMA antibody for the potential treatment of multiple myeloma — is being advanced as part of a new collaboration between AbbVie, Teneobio, and its affiliate TeneoOne. Under terms of the agreement, TeneoOne will continue to develop TNB-383B through Phase 1 clinical…

This post was originally published on this site The Multiple Myeloma Research Foundation (MMRF) is reworking its executive team, with a focus on improving multiple myeloma patient outcomes and advancing its precision medicine program. Steve Labkoff, MD, becomes the organization’s first chief data officer, while Michael Andreini is the new chief operating officer. Meanwhile, Daniel Auclair,…

This post was originally published on this site Losartan, a medicine used for treating high blood pressure, might improve ovarian cancer treatment by making it easier for chemotherapy drugs to get to tumor cells, a study found. Patients with advanced ovarian cancer receiving losartan or other similar angiotensin signaling inhibitors lived a median 30 months longer on standard…